314 related articles for article (PubMed ID: 28540931)
1. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism.
Wada N; Shibayama Y; Umakoshi H; Ichijo T; Fujii Y; Kamemura K; Kai T; Sakamoto R; Ogo A; Matsuda Y; Fukuoka T; Tsuiki M; Suzuki T; Naruse M
J Hum Hypertens; 2017 Oct; 31(10):627-632. PubMed ID: 28540931
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
3. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
4. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
5. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
8. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
10. Incidence and factors of post-adrenalectomy hyperkalemia in patients with aldosterone producing adenoma.
Chiang WF; Cheng CJ; Wu ST; Sun GH; Lin MY; Sung CC; Lin SH
Clin Chim Acta; 2013 Sep; 424():114-8. PubMed ID: 23727469
[TBL] [Abstract][Full Text] [Related]
11. Contralateral suppression of aldosterone at adrenal venous sampling predicts hyperkalemia following adrenalectomy for primary aldosteronism.
Shariq OA; Bancos I; Cronin PA; Farley DR; Richards ML; Thompson GB; Young WF; McKenzie TJ
Surgery; 2018 Jan; 163(1):183-190. PubMed ID: 29129366
[TBL] [Abstract][Full Text] [Related]
12. Severe hyperkalemia following adrenalectomy for aldosteronoma: prediction, pathogenesis and approach to clinical management- a case series.
Tahir A; McLaughlin K; Kline G
BMC Endocr Disord; 2016 Jul; 16(1):43. PubMed ID: 27460219
[TBL] [Abstract][Full Text] [Related]
13. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
[TBL] [Abstract][Full Text] [Related]
14. Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism.
Onohara T; Takagi T; Yoshida K; Iizuka J; Okumi M; Kondo T; Ishida H; Tanabe K
Int J Urol; 2019 Feb; 26(2):229-233. PubMed ID: 30384394
[TBL] [Abstract][Full Text] [Related]
15. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
16. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
Gwoo S; Kim YN; Shin HS; Jung YS; Rim H
Nephron Clin Pract; 2014; 128(3-4):381-6. PubMed ID: 25572273
[TBL] [Abstract][Full Text] [Related]
17. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
18. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma.
Park KS; Kim JH; Ku EJ; Hong AR; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Eur J Endocrinol; 2015 Jun; 172(6):725-31. PubMed ID: 25766046
[TBL] [Abstract][Full Text] [Related]
19. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
20. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
